Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DHCR7 | Q9UBM7 | 3/20 | 0.34 |
| ▸ | EBP | Q15125 | 2/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24718192 | 1.00 | KDM4E (0.35) | KDM4EPOLBDHCR7EBPHSD11B1 | |
| SCHEMBL24480312 | 0.96 | KDM4E (0.40) | KDM4EPOLBDHCR7EBPHSD11B1 | |
| SCHEMBL10190128 | 0.83 | KDM4E (0.39) | KDM4EPOLBDHCR7EBPALDH1A1 | |
| SCHEMBL24718322 | 0.83 | HSD11B1 (0.32) | HSD11B1 | |
| SCHEMBL29335376 | 0.81 | LMNA (0.32) | KDM4EHSD11B1 | |
| SCHEMBL24995530 | 0.79 | HRH3 (0.37) | HSD11B1ALDH1A1 | |
| SCHEMBL24718323 | 0.79 | HRH3 (0.37) | HSD11B1ALDH1A1 | |
| SCHEMBL24996299 | 0.79 | HRH3 (0.34) | HSD11B1 | |
| SCHEMBL22737161 | 0.79 | KDM4E (0.40) | KDM4EPOLBDHCR7EBPALDH1A1 | |
| SCHEMBL26419436 | 0.78 | KDM4E (0.33) | KDM4EPOLBDHCR7MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | KDM4E 665/4885POLB 4057/4885DHCR7 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.